<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04798781</url>
  </required_header>
  <id_info>
    <org_study_id>IIT2020-11-Hendifar-TELAT</org_study_id>
    <nct_id>NCT04798781</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Telatinib in Combination With Keytruda in Subjects With Advanced Stomach and Gastroesophageal Junction Cancers or Hepatocellular Carcinoma</brief_title>
  <official_title>A Phase II Study Evaluating Safety and Efficacy of Telatinib in Combination With Keytruda in Subjects With Advanced Stomach and Gastroesophageal Junction Cancers or Hepatocellular Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Andrew Hendifar, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>EOC Pharma</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Cedars-Sinai Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase II, single arm, open-label study of two parallel cohorts (advanced stomach&#xD;
      and gastroesophageal junction cancer and hepatocellular carcinoma), evaluating the effects of&#xD;
      telatinib in combination with Keytruda on progression-free survival.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 28, 2021</start_date>
  <completion_date type="Anticipated">February 2024</completion_date>
  <primary_completion_date type="Anticipated">February 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>from the start of treatment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 10 years</time_frame>
    <description>Duration of time from start of treatment until progression or death, whichever comes first</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall response rate</measure>
    <time_frame>from the start of treatment until the end of treatment, approximately 12 months</time_frame>
    <description>The percentage of patients who have a partial or complete response to treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate</measure>
    <time_frame>from the start of treatment until the end of treatment, approximately 12 months</time_frame>
    <description>The percentage of patients who have stable disease, partial response, or complete response to treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>from the start of treatment until the end of follow-up, approximately 18 months</time_frame>
    <description>The length of time from the start of treatment that patients are still alive</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and severity of adverse events</measure>
    <time_frame>from the start of treatment until 30 days following the end of treatment or until initiation of a new anticancer therapy (whichever occurs first), approximately 13 months</time_frame>
    <description>Incidence and severity of adverse events as measured by the National Cancer Institute Common Terminology Criteria for Adverse Events Version 5</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Gastric Cancer</condition>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>telatinib + Keytruda</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Telatinib</intervention_name>
    <description>900mg by mouth twice daily until disease progression, intolerable toxicities, or withdrawal of consent</description>
    <arm_group_label>telatinib + Keytruda</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Keytruda</intervention_name>
    <description>200mg intravenous infusion every three weeks until disease progression, intolerable toxicities, or withdrawal of consent</description>
    <arm_group_label>telatinib + Keytruda</arm_group_label>
    <other_name>pembrolizumab</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis: Histologically confirmed gastric/esophagealgastric adenocarcinoma,&#xD;
             recurrent, locally advanced or metastatic, PD-L1-positive disease (CPS â‰¥1), progressed&#xD;
             on at least two prior lines of therapy and/or discontinued second line therapy for&#xD;
             intolerance, indicated for Keytruda therapy. OR: Hepatocellular carcinoma with&#xD;
             diagnosis confirmed by histologic or cytologic analysis or clinical features according&#xD;
             to the American Association for the Study of Liver Diseases criteria for patients with&#xD;
             cirrhosis, unresectable disease not amenable to locoregional therapy with disease&#xD;
             progression after at least one prior line of systemic therapy or discontinued first&#xD;
             line therapy for intolerance.&#xD;
&#xD;
          -  At least 1 measurable metastatic lesion that has not been irradiated. The lesion will&#xD;
             be measured according to Response Evaluation Criteria in Solid Tumors (RECIST 1.1),&#xD;
             and be documented by radiological evaluation within 28 days prior to registration. For&#xD;
             subjects with locally advanced disease: at least one measurable lesion that has not&#xD;
             been irradiated, documented by radiological evaluation within 28 days prior to&#xD;
             registration.&#xD;
&#xD;
          -  Any prior radiation therapy must be completed at least 28 days prior to the first dose&#xD;
             of study treatment.&#xD;
&#xD;
          -  Eighteen years of age or older.&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance score of 0, 1 or 2.&#xD;
&#xD;
          -  Adequate bone marrow, liver, and renal function&#xD;
&#xD;
          -  Negative urine or serum pregnancy test for women of childbearing potential.&#xD;
&#xD;
          -  Women and men of childbearing potential must agree to use adequate contraception prior&#xD;
             to registration, for the duration of study participation and until 4 months after the&#xD;
             last study drug dosing.&#xD;
&#xD;
          -  Able to swallow tablets.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Clinical or radiographic evidence of current brain metastasis. History of treated&#xD;
             brain metastases is allowable.&#xD;
&#xD;
          -  Cardiac disease&#xD;
&#xD;
          -  Uncontrolled hypertension&#xD;
&#xD;
          -  Severe hemorrhage/bleeding event within 28 days prior to the first dose of study&#xD;
             treatment&#xD;
&#xD;
          -  Major surgery, open biopsy, or significant traumatic injury within 42 days prior to&#xD;
             the first dose of study treatment&#xD;
&#xD;
          -  Current serious, nonhealing wound, ulcer, or bone fracture within 42 days prior to the&#xD;
             first dose of study treatment&#xD;
&#xD;
          -  History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess&#xD;
             within 6 months prior to the first dose of study treatment.&#xD;
&#xD;
          -  Presence of an uncontrolled infection or infection that required intravenous&#xD;
             antibiotics, antifungals, or antivirals within 14 days prior to the first dose of&#xD;
             study treatment.&#xD;
&#xD;
          -  Known human immunodeficiency virus (HIV) infection. HIV-infected subjects on effective&#xD;
             anti-retroviral therapy are eligible if the most recent viral load test performed&#xD;
             within six months of screening (based on medical chart review) is negative. The safety&#xD;
             of telatinib in this subject population has not been studied.&#xD;
&#xD;
          -  Known chronic hepatitis B, unless receiving antiviral treatment and HBV DNA test&#xD;
             performed within six months of screening (based on medical chart review) is &lt;2000&#xD;
             IU/ML.&#xD;
&#xD;
          -  Known Child-Pugh Score B or C liver cirrhosis.&#xD;
&#xD;
          -  Diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other&#xD;
             form of immunosuppressive therapy within 7 days prior to the first dose of study&#xD;
             treatment or has been diagnosed with an autoimmune disease that has required systemic&#xD;
             treatment in the past 2 years (i.e., with use of disease modifying agents,&#xD;
             corticosteroids, or immunosuppressive drugs). Patients that require replacement&#xD;
             therapy (e.g., thyroxine [T4], insulin, or physiologic corticosteroid replacement&#xD;
             therapy for adrenal or pituitary insufficiency, etc.) may be enrolled.&#xD;
&#xD;
          -  History of (non-infectious) pneumonitis that required steroids, or current&#xD;
             pneumonitis, or has a history of interstitial lung disease.&#xD;
&#xD;
          -  Has received a live-virus vaccination within 30 days of planned treatment start.&#xD;
&#xD;
          -  Known history of proteinuria &gt; 1gr/24 hours.&#xD;
&#xD;
          -  Previous or concurrent cancer that is distinct in primary site or histology from the&#xD;
             current stomach or liver cancer. Subjects with cervical cancer in-situ, treated basal&#xD;
             cell carcinoma, superficial bladder tumors (Ta and Tis) or any cancer curatively&#xD;
             treated are not excluded.&#xD;
&#xD;
          -  Anti-cancer therapy (chemotherapy, hormonal therapy, radiation therapy, surgery,&#xD;
             immunotherapy, biologic therapy, or tumor embolization) or investigational agent&#xD;
             within 28 days prior to the first dose of study treatment.&#xD;
&#xD;
          -  Known or suspected allergy to any component of telatinib or Keytruda&#xD;
&#xD;
          -  Prior or current history of substance abuse, or medical, psychological, or social&#xD;
             condition that in the opinion of the investigator may interfere with the subject's&#xD;
             participation in the study or evaluation of the study result.&#xD;
&#xD;
          -  Women who are pregnant or breastfeeding.&#xD;
&#xD;
          -  Prior history of thromboembolic disease, e.g., deep vein thrombosis (DVT), pulmonary&#xD;
             emboli (PE), within 6 months prior to the first dose of study treatment that has&#xD;
             required continued medical intervention.&#xD;
&#xD;
          -  Baseline peripheral neuropathy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrew Hendifar, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cedars-Sinai Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Amy Oppenheim</last_name>
    <phone>310-423-3713</phone>
    <email>Amy.Oppenheim@cshs.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Tower Hematology Oncology Medical Group</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <zip>90211</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kortnee Calkins</last_name>
      <phone>310-285-7210</phone>
      <email>Kortnee.Calkins@cshs.org</email>
    </contact>
    <investigator>
      <last_name>David Hoffman, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jeremy Lorber, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kevin Scher, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Angeles Clinic and Research Institute</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90025</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jamie Perez</last_name>
      <email>jperez@theangelesclinic.org</email>
    </contact>
    <investigator>
      <last_name>Vi Chiu, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ani Balmanoukian, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Cathie Chung, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rodolfo Gutierrez, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Omid Hamid, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kristopher Wentzel, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michelle Offner, NP</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cedars-Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amy Oppenheim</last_name>
      <phone>310-423-3713</phone>
      <email>Amy.Oppenheim@cshs.org</email>
    </contact>
    <investigator>
      <last_name>Andrew Hendifar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jun Gong, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Arsen Osipov, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ju Dong Yang, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Torrance Memorial Physician Network Cancer Care Physicians</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90505</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Courtney Steeneken, RN</last_name>
      <email>Courtney.Steeneken@tmphysicians.com</email>
    </contact>
    <investigator>
      <last_name>Syed Jilani, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>David Chan, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Vanessa Dickey, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hugo Hool, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andrew Horodner, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thomas Lowe, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Swati Sikaria, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>February 24, 2021</study_first_submitted>
  <study_first_submitted_qc>March 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 15, 2021</study_first_posted>
  <last_update_submitted>November 2, 2021</last_update_submitted>
  <last_update_submitted_qc>November 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Cedars-Sinai Medical Center</investigator_affiliation>
    <investigator_full_name>Andrew Hendifar, MD</investigator_full_name>
    <investigator_title>Assistant Professor, Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

